An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone

• 作 者: Yang Shen Zhixiang Shen Bin Ji
• 机 构: DepartmentofHematology,DepartmentofHematology,DepartmentofHematology,DepartmentofHematology,Departme
• 出 处: 临床肿瘤与癌症研究：英文版
• 发表日期: 2009年6期
• 关键词: 多发性骨髓瘤 联合治疗 长春新碱 地塞米松 中国人口 聚乙二醇 阿霉素 脂质体 pegylated liposomal doxorubicin multipl
• 基金项目: We would like to thank the Phillips Group for technical assistance. Schering-Plough （China） Ltd. provided the study drug, Caelyxand a research grant.

<正> OBJECTIVE Though doxorubicin is highly activein the treatment of multiple myeloma, its toxicityprofile limits its therapeutic index. We performed thisstudy to evaluate the efficacy and safety of pegylatedliposomal doxorubicin (PLD, Caelyx~(?)),